Self-Sampling for Human Papillomavirus (HPV) at Well Women Appointments

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-07

Study Completion Date

2022-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study seeks to compare the accuracy and acceptability of Human Papillomavirus (HPV) testing self-sampling kit versus standard clinician-sampled HPV testing for cervical cancer screening. The primary outcome of this study is the concordance between screening results on self-sampling kits compared to clinician-collected HPV test and Pap smear results. Secondary endpoints will include acceptability of self-sampling and barriers to cervical cancer screening. These endpoints will be analyzed to try to circumvent barriers to the cervical cancer screening and ascertain whether self-sampling is a viable alternative to clinician sampling.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Self-sampling for Human Papillomavirus (HPV) Among Patients Receiving Colposcopy

NCT04585243

HPV

TERMINATED NA

St. Joseph's HPV Self-sampling: Offering a Self-sampling Option in Clinic

NCT05092022

Cervical Cancer Screening

RECRUITING NA

St. Joe's Invitation Effectiveness Study

NCT04658888

Cervical Cancer Screening

COMPLETED NA

The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples

NCT04423679

Human Papilloma Virus Cervical Cancer CIN 2/3

UNKNOWN

HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs

NCT04133610

Cervical Cancer Cervical Dysplasia Human Papillomavirus Infection

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The American Cancer Society estimates that 4,170 women in the United States (US) will die from cervical cancer in 2018. Screening can reduce cancer mortality by (1) detecting malignancies when they are more treatable and (2) for some tests, identifying precancerous lesions for removal. Guidelines recommend cytology and/or human papillomavirus (HPV) testing for cervical cancer screening among women ages 30-65 years, but screening rates are suboptimal.

To help bridge these gaps in screening, HPV self-sampling would be an alternative to clinical screening. However, there are concerns about the comparability and acceptability of self-sampling kits. The impact of the proposed project is to compare HPV self-screening results with Pap smear results and clinician-collected HPV tests to ultimately improve the uptake of HPV screening. This study will be conducted in a normal risk population.

Subjects who have an upcoming well-woman appointment will be identified from Penn State Health, Department of Family and Community Medicine, clinic schedules. Clinicians who are a part of the study team will identify these patients two weeks prior to their appointment and send their information to a study coordinator, who will then call these patients to provide more information and assess their interest in participating. Patients who schedule within the two week period or were not contacted by a study team member for any reason will be given a card with general information about the study at their well-woman visit so that these women can contact a study team member if they are interested. A total of 197 participants will be recruited into this study.

Interested participants will be screened for eligibility over the phone and sent a self-sampling kit through the mail with a Summary Explanation of Research form, instructions, and pre-paid mailer to return the kit. Participants may collect their sample two weeks before or after their well-woman visit. A study team member will contact the participants at different time points within the 28 day window to determine whether the sample was collected and to administer the follow-up survey.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HPV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Participants who enroll in the study will be asked to complete an HPV self-sampling test in addition to attending their well-woman visit and receiving a clinician-sampled Pap Smear/HPV test. Participants will collect the sample at home and mail it back to the Penn State Health clinical laboratory, where the results will be compared to those obtained from the Pap Smear/HPV test at their clinic appointment. Participants will also complete a follow up survey over the phone after their sample is collected.

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Self-Sampling Kit

Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.

Group Type EXPERIMENTAL

HPV Self-Sampling Kit (Evalyn Brush)

Intervention Type DEVICE

The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HPV Self-Sampling Kit (Evalyn Brush)

The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 30-65 Years
* Penn State Health, Family and Community Medicine, patient attending a well-woman visit
* Able to collect the sample within two weeks of visit
* Female
* Intact cervix
* Speaks, reads, or writes in English

Exclusion Criteria

* Pregnancy
* Cognitively Impaired
* Incarcerated
* Complete hysterectomy
* History of cervical treatment for abnormal Pap/HPV test (cryotherapy, LEEP)

Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No